ID   NQO1_RAT                Reviewed;         274 AA.
AC   P05982; Q63478;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   02-OCT-2024, entry version 191.
DE   RecName: Full=NAD(P)H dehydrogenase [quinone] 1;
DE            EC=1.6.5.2 {ECO:0000269|PubMed:1703398, ECO:0000269|PubMed:7862630, ECO:0000269|PubMed:8999809};
DE   AltName: Full=Azoreductase;
DE   AltName: Full=DT-diaphorase {ECO:0000303|PubMed:8999809};
DE            Short=DTD;
DE   AltName: Full=Menadione reductase;
DE   AltName: Full=NAD(P)H:quinone oxidoreductase 1 {ECO:0000303|PubMed:2141979};
DE   AltName: Full=Phylloquinone reductase;
DE   AltName: Full=Quinone reductase 1;
DE            Short=QR1;
GN   Name=Nqo1; Synonyms=Nmor1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=3536915; DOI=10.1016/s0021-9258(18)66789-4;
RA   Robertson J.A., Chen H.-C., Nebert D.W.;
RT   "NAD(P)H:menadione oxidoreductase. Novel purification of enzyme cDNA and
RT   complete amino acid sequence, and gene regulation.";
RL   J. Biol. Chem. 261:15794-15799(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE.
RA   Robertson J.A., Nebert D.W., Hankinson O.;
RT   "Autoregulation plus positive and negative elements controlling
RT   transcription of genes in the [Ah] battery.";
RL   Chem. Scr. 27:83-87(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Liver;
RX   PubMed=3100515; DOI=10.1016/s0021-9258(19)75821-9;
RA   Bayney R.M., Rodkey J.A., Bennett C.D., Lu A.Y.H., Pickett C.B.;
RT   "Rat liver NAD(P)H: quinone reductase nucleotide sequence analysis of a
RT   quinone reductase cDNA clone and prediction of the amino acid sequence of
RT   the corresponding protein.";
RL   J. Biol. Chem. 262:572-575(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Liver;
RX   PubMed=2480957; DOI=10.1016/s0021-9258(20)88253-2;
RA   Bayney R.M., Morton M.R., Favreau L.V., Pickett C.B.;
RT   "Rat liver NAD(P)H:quinone reductase. Regulation of quinone reductase gene
RT   expression by planar aromatic compounds and determination of the exon
RT   structure of the quinone reductase structural gene.";
RL   J. Biol. Chem. 264:21793-21797(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Heart;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 2-274, CLEAVAGE OF INITIATOR METHIONINE, AND
RP   ACETYLATION AT ALA-2.
RX   PubMed=3143406; DOI=10.1021/bi00418a033;
RA   Haniu M., Yuan H., Chen S.A., Iyanagi T., Lee T.D., Shively J.E.;
RT   "Structure-function relationship of NAD(P)H:quinone reductase:
RT   characterization of NH2-terminal blocking group and essential tyrosine and
RT   lysine residues.";
RL   Biochemistry 27:6877-6883(1988).
RN   [7]
RP   NUCLEOTIDE SEQUENCE OF 1-57.
RX   PubMed=2963593; DOI=10.1016/0003-9861(88)90516-4;
RA   Bayney R.M., Pickett C.B.;
RT   "Rat liver NAD(P)H:quinone reductase: isolation of a quinone reductase
RT   structural gene and prediction of the NH2 terminal sequence of the protein
RT   by double-stranded sequencing of exons 1 and 2.";
RL   Arch. Biochem. Biophys. 260:847-850(1988).
RN   [8]
RP   PROTEIN SEQUENCE OF 2-21, FUNCTION, COFACTOR, SUBCELLULAR LOCATION, AND
RP   CATALYTIC ACTIVITY.
RX   PubMed=1703398; DOI=10.1016/0003-9861(90)90648-i;
RA   Ma Q., Wang R., Yang C.S., Lu A.Y.H.;
RT   "Expression of mammalian DT-diaphorase in Escherichia coli: purification
RT   and characterization of the expressed protein.";
RL   Arch. Biochem. Biophys. 283:311-317(1990).
RN   [9]
RP   PROTEIN SEQUENCE OF 24-131 AND 156-270.
RX   PubMed=3144286; DOI=10.1016/0006-2952(88)90336-x;
RA   Knox R.J., Boland M.P., Friedlos F., Coles B., Southan C., Roberts J.J.;
RT   "The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-
RT   yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-
RT   nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC
RT   1.6.99.2).";
RL   Biochem. Pharmacol. 37:4671-4677(1988).
RN   [10]
RP   NUCLEOTIDE SEQUENCE OF 80-274.
RX   PubMed=2504488;
RA   Dear T.N., McDonald D.A., Kefford R.F.;
RT   "Transcriptional down-regulation of a rat gene, WDNM2, in metastatic DMBA-8
RT   cells.";
RL   Cancer Res. 49:5323-5328(1989).
RN   [11]
RP   PROTEIN SEQUENCE OF 147-156 AND 263-271.
RX   PubMed=2499768;
RA   Liu X.F., Yuan H., Haniu M., Iyanagi T., Shively J.E., Chen S.A.;
RT   "Reaction of rat liver DT-diaphorase (NAD(P)H:quinone acceptor reductase)
RT   with 5'-[p-(fluorosulfonyl)benzoyl]-adenosine.";
RL   Mol. Pharmacol. 35:818-822(1989).
RN   [12]
RP   MUTAGENESIS OF 117-PHE--GLU-118; VAL-161 AND ASP-164.
RX   PubMed=2141979; DOI=10.1016/0006-291x(90)92006-l;
RA   Forrest G.L., Qian J., Ma J.-X., Kaplan W.D., Akman S., Doroshow J.,
RA   Chen S.A.;
RT   "Rat liver NAD(P)H:quinone oxidoreductase: cDNA expression and site-
RT   directed mutagenesis.";
RL   Biochem. Biophys. Res. Commun. 169:1087-1093(1990).
RN   [13]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   MUTAGENESIS OF HIS-195.
RX   PubMed=7862630; DOI=10.1073/pnas.92.4.1043;
RA   Cui K., Lu A.Y., Yang C.S.;
RT   "Subunit functional studies of NAD(P)H:quinone oxidoreductase with a
RT   heterodimer approach.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:1043-1047(1995).
RN   [14]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   MUTAGENESIS OF TYR-105; THR-131; VAL-204; SER-219 AND LEU-239.
RX   PubMed=8999809; DOI=10.1074/jbc.272.3.1437;
RA   Chen S., Knox R., Wu K., Deng P.S., Zhou D., Bianchet M.A., Amzel L.M.;
RT   "Molecular basis of the catalytic differences among DT-diaphorase of human,
RT   rat, and mouse.";
RL   J. Biol. Chem. 272:1437-1439(1997).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEX WITH FAD AND DUROQUINONE,
RP   AND SUBUNIT.
RC   TISSUE=Liver;
RX   PubMed=7568029; DOI=10.1073/pnas.92.19.8846;
RA   Li R., Bianchet M.A., Talalay P., Amzel L.M.;
RT   "The three-dimensional structure of NAD(P)H:quinone reductase, a
RT   flavoprotein involved in cancer chemoprotection and chemotherapy: mechanism
RT   of the two-electron reduction.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:8846-8850(1995).
RN   [16]
RP   ERRATUM OF PUBMED:7568029.
RA   Li R., Bianchet M.A., Talalay P., Amzel L.M.;
RL   Proc. Natl. Acad. Sci. U.S.A. 92:10815-10815(1995).
CC   -!- FUNCTION: Flavin-containing quinone reductase that catalyzes two-
CC       electron reduction of quinones to hydroquinones using either NADH or
CC       NADPH as electron donors. In a ping-pong kinetic mechanism, the
CC       electrons are sequentially transferred from NAD(P)H to flavin cofactor
CC       and then from reduced flavin to the quinone, bypassing the formation of
CC       semiquinone and reactive oxygen species (PubMed:1703398,
CC       PubMed:7862630, PubMed:8999809). Regulates cellular redox state
CC       primarily through quinone detoxification. Reduces components of plasma
CC       membrane redox system such as coenzyme Q and vitamin quinones,
CC       producing antioxidant hydroquinone forms. In the process may function
CC       as superoxide scavenger to prevent hydroquinone oxidation and
CC       facilitate excretion (By similarity). Alternatively, can activate
CC       quinones and their derivatives by generating redox reactive
CC       hydroquinones with DNA cross-linking antitumor potential (By
CC       similarity). Acts as a gatekeeper of the core 20S proteasome known to
CC       degrade proteins with unstructured regions. Upon oxidative stress,
CC       interacts with tumor suppressors TP53 and TP73 in a NADH-dependent way
CC       and inhibits their ubiquitin-independent degradation by the 20S
CC       proteasome (By similarity). {ECO:0000250|UniProtKB:P15559,
CC       ECO:0000269|PubMed:1703398, ECO:0000269|PubMed:7862630,
CC       ECO:0000269|PubMed:8999809}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a quinone + H(+) + NADH = a quinol + NAD(+);
CC         Xref=Rhea:RHEA:46160, ChEBI:CHEBI:15378, ChEBI:CHEBI:24646,
CC         ChEBI:CHEBI:57540, ChEBI:CHEBI:57945, ChEBI:CHEBI:132124; EC=1.6.5.2;
CC         Evidence={ECO:0000269|PubMed:1703398, ECO:0000269|PubMed:7862630,
CC         ECO:0000269|PubMed:8999809};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46161;
CC         Evidence={ECO:0000305|PubMed:1703398, ECO:0000305|PubMed:7862630,
CC         ECO:0000305|PubMed:8999809};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a quinone + H(+) + NADPH = a quinol + NADP(+);
CC         Xref=Rhea:RHEA:46164, ChEBI:CHEBI:15378, ChEBI:CHEBI:24646,
CC         ChEBI:CHEBI:57783, ChEBI:CHEBI:58349, ChEBI:CHEBI:132124; EC=1.6.5.2;
CC         Evidence={ECO:0000269|PubMed:1703398, ECO:0000269|PubMed:7862630};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46165;
CC         Evidence={ECO:0000305|PubMed:1703398, ECO:0000305|PubMed:7862630};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H(+) + NADH + ubiquinone-10 = NAD(+) + ubiquinol-10;
CC         Xref=Rhea:RHEA:61984, ChEBI:CHEBI:15378, ChEBI:CHEBI:46245,
CC         ChEBI:CHEBI:57540, ChEBI:CHEBI:57945, ChEBI:CHEBI:64183;
CC         Evidence={ECO:0000250|UniProtKB:P15559};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:61985;
CC         Evidence={ECO:0000250|UniProtKB:P15559};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H(+) + menadione + NADH = menadiol + NAD(+);
CC         Xref=Rhea:RHEA:69695, ChEBI:CHEBI:6746, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:28869, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945;
CC         Evidence={ECO:0000269|PubMed:8999809};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:69696;
CC         Evidence={ECO:0000305|PubMed:8999809};
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692;
CC         Evidence={ECO:0000269|PubMed:1703398};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=85 uM for NADH {ECO:0000269|PubMed:7862630};
CC         KM=39 uM for NADPH {ECO:0000269|PubMed:7862630};
CC         KM=110 uM for NADH {ECO:0000269|PubMed:8999809};
CC         KM=2.5 uM for menadione {ECO:0000269|PubMed:8999809};
CC         KM=840 uM for 5-(aziridin-1-yl)-2,4-dinitrobenzamide
CC         {ECO:0000269|PubMed:8999809};
CC         Vmax=2400 umol/min/mg enzyme toward menadione
CC         {ECO:0000269|PubMed:8999809};
CC         Vmax=140 nmol/min/mg enzyme toward 5-(aziridin-1-yl)-2,4-
CC         dinitrobenzamide {ECO:0000269|PubMed:8999809};
CC         Note=kcat is 0.075 min(-1) NADH with as substrate. kcat is 0.074
CC         min(-1) with NADPH as substrate. {ECO:0000269|PubMed:7862630};
CC   -!- SUBUNIT: Homodimer (PubMed:7568029). Interacts with PDLIM4 isoform 2;
CC       this interaction stabilizes PDLIM4 isoform 2 in response to oxidative
CC       stress and protects it from ubiquitin-independent degradation by the
CC       core 20S proteasome (By similarity). Interacts with TP73 (via SAM
CC       domain); this interaction is NADH-dependent, stabilizes TP73 in
CC       response to oxidative stress and protects it from ubiquitin-independent
CC       degradation by the 20S proteasome (By similarity). Interacts with TP53;
CC       this interaction is NADH-dependent, stabilizes TP53 in response to
CC       oxidative stress and protects it from ubiquitin-independent degradation
CC       by the 20S proteasome (By similarity). {ECO:0000250|UniProtKB:P15559,
CC       ECO:0000269|PubMed:7568029}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:1703398}.
CC   -!- INDUCTION: By polycyclic hydrocarbons (Governed by the aromatic
CC       hydrocarbon-responsive (AH) locus).
CC   -!- MISCELLANEOUS: Quinone reductase accepts electrons from both NADH and
CC       NADPH with equal efficiency.
CC   -!- MISCELLANEOUS: This protein is inhibited by dicoumarol.
CC   -!- SIMILARITY: Belongs to the NAD(P)H dehydrogenase (quinone) family.
CC       {ECO:0000305}.
CC   -!- CAUTION: PubMed:2480957 sequence seems incorrectly to be attributed to
CC       a mouse sequence while it really seems to correspond to the rat
CC       sequence. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA41988.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; J02608; AAA41716.1; -; mRNA.
DR   EMBL; J02679; AAA41715.1; -; mRNA.
DR   EMBL; M36660; AAA39829.1; -; mRNA.
DR   EMBL; J02640; AAA41988.1; ALT_INIT; mRNA.
DR   EMBL; M31805; AAA41989.1; -; Genomic_DNA.
DR   EMBL; M31801; AAA41989.1; JOINED; Genomic_DNA.
DR   EMBL; M31802; AAA41989.1; JOINED; Genomic_DNA.
DR   EMBL; M31804; AAA41989.1; JOINED; Genomic_DNA.
DR   EMBL; M33039; AAA41990.1; -; Genomic_DNA.
DR   EMBL; M33038; AAA41990.1; JOINED; Genomic_DNA.
DR   EMBL; BC083542; AAH83542.1; -; mRNA.
DR   EMBL; X17464; -; NOT_ANNOTATED_CDS; mRNA.
DR   PIR; A34162; A34162.
DR   RefSeq; NP_058696.2; NM_017000.3.
DR   PDB; 1QRD; X-ray; 2.40 A; A/B=2-274.
DR   PDBsum; 1QRD; -.
DR   AlphaFoldDB; P05982; -.
DR   SMR; P05982; -.
DR   IntAct; P05982; 2.
DR   STRING; 10116.ENSRNOP00000017175; -.
DR   BindingDB; P05982; -.
DR   ChEMBL; CHEMBL3091269; -.
DR   DrugCentral; P05982; -.
DR   iPTMnet; P05982; -.
DR   PhosphoSitePlus; P05982; -.
DR   jPOST; P05982; -.
DR   PaxDb; 10116-ENSRNOP00000017175; -.
DR   Ensembl; ENSRNOT00000112166.1; ENSRNOP00000082814.1; ENSRNOG00000012772.6.
DR   Ensembl; ENSRNOT00055035578; ENSRNOP00055028854; ENSRNOG00055020832.
DR   Ensembl; ENSRNOT00060022275; ENSRNOP00060017661; ENSRNOG00060013067.
DR   Ensembl; ENSRNOT00065018126; ENSRNOP00065013810; ENSRNOG00065011197.
DR   GeneID; 24314; -.
DR   KEGG; rno:24314; -.
DR   UCSC; RGD:2503; rat.
DR   AGR; RGD:2503; -.
DR   CTD; 1728; -.
DR   RGD; 2503; Nqo1.
DR   eggNOG; ENOG502QQMI; Eukaryota.
DR   GeneTree; ENSGT00940000159150; -.
DR   HOGENOM; CLU_058643_2_0_1; -.
DR   InParanoid; P05982; -.
DR   OMA; LFPIHHG; -.
DR   OrthoDB; 5471423at2759; -.
DR   PhylomeDB; P05982; -.
DR   TreeFam; TF300296; -.
DR   BRENDA; 1.6.5.2; 5301.
DR   Reactome; R-RNO-350562; Regulation of ornithine decarboxylase (ODC).
DR   EvolutionaryTrace; P05982; -.
DR   PRO; PR:P05982; -.
DR   Proteomes; UP000002494; Chromosome 19.
DR   Bgee; ENSRNOG00000012772; Expressed in stomach and 20 other cell types or tissues.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005829; C:cytosol; ISO:RGD.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0003955; F:NAD(P)H dehydrogenase (quinone) activity; IDA:RGD.
DR   GO; GO:0050136; F:NADH:ubiquinone reductase (non-electrogenic) activity; IDA:UniProtKB.
DR   GO; GO:0008753; F:NADPH dehydrogenase (quinone) activity; IEA:RHEA.
DR   GO; GO:0004784; F:superoxide dismutase activity; IMP:RGD.
DR   GO; GO:0045454; P:cell redox homeostasis; ISO:RGD.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IDA:RGD.
DR   GO; GO:0071248; P:cellular response to metal ion; IEP:RGD.
DR   GO; GO:0034599; P:cellular response to oxidative stress; ISO:RGD.
DR   GO; GO:0045087; P:innate immune response; ISO:RGD.
DR   GO; GO:0006116; P:NADH oxidation; IDA:RGD.
DR   GO; GO:0070995; P:NADPH oxidation; IDA:RGD.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:RGD.
DR   GO; GO:0110076; P:negative regulation of ferroptosis; ISS:UniProtKB.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; ISS:UniProtKB.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IMP:RGD.
DR   GO; GO:0030163; P:protein catabolic process; ISO:RGD.
DR   GO; GO:0000209; P:protein polyubiquitination; ISO:RGD.
DR   GO; GO:0019430; P:removal of superoxide radicals; ISS:UniProtKB.
DR   GO; GO:0043279; P:response to alkaloid; IEP:RGD.
DR   GO; GO:0014075; P:response to amine; IDA:RGD.
DR   GO; GO:0009743; P:response to carbohydrate; IEP:RGD.
DR   GO; GO:0051602; P:response to electrical stimulus; IEP:RGD.
DR   GO; GO:0032355; P:response to estradiol; IEP:RGD.
DR   GO; GO:0045471; P:response to ethanol; IEP:RGD.
DR   GO; GO:1905395; P:response to flavonoid; IEP:RGD.
DR   GO; GO:0009725; P:response to hormone; IEP:RGD.
DR   GO; GO:1904880; P:response to hydrogen sulfide; IEP:RGD.
DR   GO; GO:0002931; P:response to ischemia; IEP:RGD.
DR   GO; GO:1904844; P:response to L-glutamine; IDA:RGD.
DR   GO; GO:0032496; P:response to lipopolysaccharide; ISO:RGD.
DR   GO; GO:0007584; P:response to nutrient; IEP:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEP:RGD.
DR   GO; GO:0006979; P:response to oxidative stress; IEP:RGD.
DR   GO; GO:0033574; P:response to testosterone; IEP:RGD.
DR   GO; GO:1904772; P:response to tetrachloromethane; IEP:RGD.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IDA:RGD.
DR   GO; GO:0006801; P:superoxide metabolic process; IMP:RGD.
DR   GO; GO:0006743; P:ubiquinone metabolic process; ISS:UniProtKB.
DR   GO; GO:0042360; P:vitamin E metabolic process; ISS:UniProtKB.
DR   GO; GO:0042373; P:vitamin K metabolic process; IDA:UniProtKB.
DR   Gene3D; 3.40.50.360; -; 1.
DR   InterPro; IPR003680; Flavodoxin_fold.
DR   InterPro; IPR029039; Flavoprotein-like_sf.
DR   InterPro; IPR051545; NAD(P)H_dehydrogenase_qn.
DR   PANTHER; PTHR10204; NAD P H OXIDOREDUCTASE-RELATED; 1.
DR   PANTHER; PTHR10204:SF1; NAD(P)H DEHYDROGENASE [QUINONE] 1; 1.
DR   Pfam; PF02525; Flavodoxin_2; 1.
DR   SUPFAM; SSF52218; Flavoproteins; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cytoplasm; Direct protein sequencing; FAD;
KW   Flavoprotein; Isopeptide bond; NAD; NADP; Oxidoreductase; Phosphoprotein;
KW   Reference proteome; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:1703398,
FT                   ECO:0000269|PubMed:3143406"
FT   CHAIN           2..274
FT                   /note="NAD(P)H dehydrogenase [quinone] 1"
FT                   /id="PRO_0000071625"
FT   REGION          225..274
FT                   /note="Important for apoenzyme conformational stability"
FT                   /evidence="ECO:0000250|UniProtKB:P15559"
FT   BINDING         12
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000269|PubMed:7568029"
FT   BINDING         18..19
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000269|PubMed:7568029"
FT   BINDING         67
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000269|PubMed:7568029"
FT   BINDING         104..107
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000269|PubMed:7568029"
FT   BINDING         126..128
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         148..151
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000269|PubMed:7568029"
FT   BINDING         156
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000269|PubMed:7568029"
FT   BINDING         201
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000269|PubMed:7568029"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000269|PubMed:3143406"
FT   MOD_RES         82
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P15559"
FT   CROSSLNK        251
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P15559"
FT   MUTAGEN         105
FT                   /note="Y->Q: Decreases the catalytic efficiency toward
FT                   menadione and nitrobenzene substrates."
FT                   /evidence="ECO:0000269|PubMed:8999809"
FT   MUTAGEN         117..118
FT                   /note="FE->KK: Destroys enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:2141979"
FT   MUTAGEN         131
FT                   /note="T->A: Decreases the catalytic efficiency toward
FT                   menadione. Has no effect on the catalytic efficiency toward
FT                   nitrobenzene substrate."
FT                   /evidence="ECO:0000269|PubMed:8999809"
FT   MUTAGEN         161
FT                   /note="V->D: Destroys enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:2141979"
FT   MUTAGEN         164
FT                   /note="D->Q: Destroys enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:2141979"
FT   MUTAGEN         195
FT                   /note="H->A: Induces a very low catalytic efficiency."
FT                   /evidence="ECO:0000269|PubMed:7862630"
FT   MUTAGEN         204
FT                   /note="V->I: Has no effect on the catalytic efficiency
FT                   toward menadione and nitrobenzene substrates."
FT                   /evidence="ECO:0000269|PubMed:8999809"
FT   MUTAGEN         219
FT                   /note="S->T: Has no effect on the catalytic efficiency
FT                   toward menadione and nitrobenzene substrates."
FT                   /evidence="ECO:0000269|PubMed:8999809"
FT   MUTAGEN         239
FT                   /note="L->M: Has no effect on the catalytic efficiency
FT                   toward menadione. Slightly decreases the catalytic
FT                   efficiency toward nitrobenzene substrate."
FT                   /evidence="ECO:0000269|PubMed:8999809"
FT   CONFLICT        31
FT                   /note="Missing (in Ref. 9; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        80
FT                   /note="R -> G (in Ref. 10; X17464)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        135
FT                   /note="K -> Q (in Ref. 3; AAA41988)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        216
FT                   /note="W -> E (in Ref. 9; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        227
FT                   /note="S -> E (in Ref. 9; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        263
FT                   /note="S -> I (in Ref. 9; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        269
FT                   /note="Q -> E (in Ref. 11; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   STRAND          5..10
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   HELIX           18..32
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   STRAND          36..41
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   TURN            42..46
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   HELIX           53..55
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   HELIX           68..78
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   HELIX           83..94
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   STRAND          96..103
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   HELIX           111..120
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   TURN            123..125
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   HELIX           133..135
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   TURN            137..140
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   STRAND          142..148
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   HELIX           153..156
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   HELIX           165..173
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   HELIX           174..178
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   TURN            179..181
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   STRAND          188..190
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   HELIX           193..195
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   HELIX           198..212
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   HELIX           215..217
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   HELIX           226..228
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   TURN            233..236
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   HELIX           241..247
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   STRAND          254..256
FT                   /evidence="ECO:0007829|PDB:1QRD"
FT   TURN            266..270
FT                   /evidence="ECO:0007829|PDB:1QRD"
SQ   SEQUENCE   274 AA;  30947 MW;  40E8801320A20F09 CRC64;
     MAVRRALIVL AHAERTSFNY AMKEAAVEAL KKKGWEVVES DLYAMNFNPL ISRNDITGEP
     KDSENFQYPV ESSLAYKEGR LSPDIVAEQK KLEAADLVIF QFPLYWFGVP AILKGWFERV
     LVAGFAYTYA TMYDKGPFQN KKTLLSITTG GSGSMYSLQG VHGDMNVILW PIQSGILRFC
     GFQVLEPQLV YSIGHTPPDA RVQVLEGWKK RLETVWEESP LYFAPSSLFD LNFQAGFLLK
     KEVQEEQKKN KFGLSVGHHL GKSIPADNQI KARK
//
